Basic Stats
| LEI | 529900GNNJPNM4XHXQ77 |
| CIK | 1116463 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OraSure Technologies, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 6, 2025 |
Third Amended and Restated Bylaws of OraSure Technologies, Inc. as of August 5, 2025. EXHIBIT 3.2 THIRD AMENDED AND RESTATED BYLAWS OF ORASURE TECHNOLOGIES, INC. Effective as of August [5], 2025 ARTICLE I Name and Location SECTION 1. Name. The name of the Corporation shall be the name set forth in the Certificate of Incorporation. SECTION 2. Principal Office. The principal office of the Corporation is located at 220 East First Street, Bethlehem, Pennsylvania 18015-1360. SECTION 3. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2025 |
OraSure Announces Second Quarter 2025 Financial Results EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Announces Second Quarter 2025 Financial Results BETHLEHEM, PA, August 5, 2025 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solution |
|
| May 27, 2025 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 CORRESP OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 May 27, 2025 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Nicholas O’Leary Re: OraSure Technologies, Inc. Registration Statement on Form S-3 filed May 20, 2025 (File No. 333-28 |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 As filed with the Securities and Exchange Commission on May 20, 2025 Registration No. |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025. As filed with the Securities and Exchange Commission on May 20, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORASURE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4370966 (State or Other Jurisdiction of Incorporation or Organization) (IRS E |
|
| May 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OraSure Technologies, Inc. |
|
| May 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) OraSure Technologies, Inc. |
|
| May 20, 2025 |
Specimen Certificate representing shares of the Company’s $0.000001 par value Common Stock. osur-sx3xex41 Exhibit 4.1 O R A S U R E T E C H N O L O G I E S , I N C . T H E C O R P O R A T I O N W I L L F U R N I S H W I T H O U T C H A R G E T O E A C H S H A R E H O L D E R W H O S O R E Q U E S T S , A S U M M A R Y O F T H E P O W E R S , D E S I G N A T I O N S , P R E F E R E N C E S A N D R E L A T I V E , P A R T I C I P A T I N G , O P T I O N A L O R O T H E R S P E C I A L R I |
|
| May 20, 2025 |
Form of Indenture to be entered into between the Company and a Trustee acceptable to the Company. Exhibit 4.4.1 FORM OF INDENTURE ORASURE TECHNOLOGIES, INC., as Issuer, and [ ], as Trustee Indenture Dated as of [ ] Providing for the Issuance Of Debt Securities ORASURE TECHNOLOGIES, INC. Reconciliation and tie between Trust Indenture Act of 1939 and indenture, dated as of [ ] Trust Indenture Act Section Indenture Section §310 (a)(1) 6.07 (a)(2) 6.07 (b) 6.09 §311 (a) 7.06 (b) 7.06 §312 (a) 7.01 |
|
| May 14, 2025 |
Amended and Restated OraSure Technologies, Inc. 2000 Stock Award Plan. ORASURE TECHNOLOGIES, INC. STOCK AWARD PLAN ARTICLE 1 ESTABLISHMENT AND PURPOSE (Amended and Restated Effective as of March 24, 2025) Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, and the Plan was approved by shareholders of Epitope, Inc. at the 2000 annual shareholders meeting. Effective September 29, 2000, in con |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.2) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorp |
|
| May 9, 2025 |
ORASURE TECHNOLOGIES, INC. UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 ORASURE TECHNOLOGIES, INC. UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL INFORMATION On December 19, 2024, the OraSure Technologies, Inc. (the “Company”) acquired Sherlock Biosciences, Inc. (“Sherlock”), pursuant to the terms of a merger agreement (the “Merger”). In connection with the Merger, Sherlock merged with and into Project Watson Merger Sub, Inc., a wholly-owned subsidiary o |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
OraSure Announces First Quarter 2025 Financial Results EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Announces First Quarter 2025 Financial Results BETHLEHEM, PA, May 7, 2025 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, t |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| May 7, 2025 |
Exhibit 18.1 May 7, 2025 Board of Directors OraSure Technologies, Inc. 220 E 1st St. Bethlehem, PA18015 Dear Directors: We are providing this letter solely for inclusion as an exhibit to OraSure Technologies Inc. (the “Company”") Form 10-Q filing pursuant to Item 601 of Regulation S-K. As stated in Note 1 to the unaudited consolidated financial statements included in the Company’s Quarterly Report |
|
| April 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2025 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 24, 2025 |
OraSure Announces $40 Million Stock Repurchase Program EXHIBIT 99.1 Investor Contact: Jason Plagman VP, Investor Relations [email protected] Media Contact: Amy Koch Director, Corporate Communications [email protected] OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM, PA, March 24, 2025 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample mana |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-16537 |
|
| March 7, 2025 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned constitutes and appoints Michele Anthony and Stefano Taucer, and each of them, her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of Or |
|
| March 7, 2025 |
Exhibit 19.1 ORASURE TECHNOLOGIES, INC. POLICY STATEMENT ON DEALING WITH COMPANY INFORMATION, INCLUDING INSIDE INFORMATION AND INSIDER SECURITIES TRADING (Effective as of May 2, 2023) In the course of conducting the business of OraSure Technologies, Inc. (the “Company”) and its subsidiaries, you may at times have information about the Company or its subsidiaries or another entity that generally is |
|
| March 7, 2025 |
ORASURE TECHNOLOGIES, INC. UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 ORASURE TECHNOLOGIES, INC. UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL INFORMATION On December 19, 2024, the OraSure Technologies, Inc. (the “Company”) acquired Sherlock Biosciences, Inc. (“Sherlock”), pursuant to the terms of a merger agreement (the “Merger”). In connection with the Merger, Sherlock merged with and into Project Watson Merger Sub, Inc., a wholly-owned subsidiary o |
|
| March 7, 2025 |
Sherlock Biosciences, Inc. and Subsidiaries Consolidated Financial Statements For the Nine Months Ended September 30, 2024 and the Year Ended December 31, 2023 With Independent Auditors’ Report SHERLOCK BIOSCIENCES, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and the Year Ended December 31, 2023 TABLE OF CONTENTS Page Independent Auditors’ R |
|
| March 7, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorp |
|
| March 7, 2025 |
Exhibit 2.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. Agreement and Plan of Merger by and among OraSure Technologies, Inc., Project Watson Merger Sub, Inc., Sherlock Biosciences, Inc. and Mr. Paul Meister, as the S |
|
| March 7, 2025 |
Exhibit 21.1 Subsidiaries of the Registrant Subsidiary Place of Incorporation/ Organization DNA Genotek Inc. Canada Sherlock Biosciences, Inc Delaware Sherlock Securities Corporation Massachusetts 221B Foundation Delaware Sense Biodetection Limited England and Wales Sense Biodetection Inc Delaware |
|
| February 25, 2025 |
OraSure Reports Fourth Quarter 2024 Financial Results EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Fourth Quarter 2024 Financial Results BETHLEHEM, PA, February 25, 2025 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutio |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2025 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 19, 2024 |
OraSure Technologies Acquires Sherlock Biosciences EXHIBIT 99.2 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Technologies Acquires Sherlock Biosciences BETHLEHEM, PA, December 19, 2024 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management so |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 19, 2024 |
exhibit991projwatsoninv OraSure Technologies ACQUISITION OF SHERLOCK BIOSCIENCES DECEMBER 19, 2024 EXHIBIT 99. |
|
| November 6, 2024 |
EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Q3 ’24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management appli |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Nu |
|
| October 31, 2024 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 October 31, 2024 OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 October 31, 2024 VIA EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Irene Paik, James Lopez Re: ORASURE TECHNOLOGIES INC Form 8-K Filed April 12, 2024 File No. 001-16537 Dear Ladies and Gentlemen: OraSure Technologies |
|
| October 4, 2024 |
OSUR / OraSure Technologies, Inc. / Neuberger Berman Group LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ORASURE TECHNOLOGIES INC (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 5, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 12, 2024 |
As filed with the Securities and Exchange Commission on August 12, 2024 As filed with the Securities and Exchange Commission on August 12, 2024 Registration No. |
|
| August 12, 2024 |
EX-FILING FEES 2 osur-formsx8ex107amended.htm EX-FILING FEES ACTIVE/130835542.2 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OraSure Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per U |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 6, 2024 |
EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Q2 ’24 Revenue of $54.3 Million Q2 GAAP EPS of $(0.01); Q2 Non-GAAP EPS of $0.07 OraQuick® HCV Self-test is the first globally to earn WHO pre-qualification Strong momentum with Syphilis Health CheckTM launch Expan |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| June 10, 2024 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 June 10, 2024 VIA EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Irene Paik, James Lopez Re: ORASURE TECHNOLOGIES INC Form 8-K Filed April 12, 2024 File No. 001-16537 Dear Ladies and Gentlemen: OraSure T |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 17, 2024 |
Amended and Restated OraSure Technologies, Inc. 2000 Stock Award Plan. Exhibit 10.1 ORASURE TECHNOLOGIES, Inc. Stock award plan ARTICLE 1 ESTABLISHMENT AND PURPOSES (Amended and Restated Effective as of March 25, 2024) Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, and the Plan was approved by shareholders of Epitope, Inc. at the 2000 annual shareholders meeting. Effective September 29 |
|
| May 17, 2024 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ORASURE TECHNOLOGIES, INC. OraSure Technologies, Inc. (the “Corporation”), a corporation organized and existing under the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies that: 1. The name of this corporation is OraSure Technologies, Inc. The Corporation’s |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2024 |
EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Q1 ’24 Revenue of $54.1 Million Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraS |
|
| May 1, 2024 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 May 1, 2024 OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 May 1, 2024 VIA EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Baker, Al Pavot Re: ORASURE TECHNOLOGIES INC Form 10-K filed March 11, 2024 Item 2.02 Form 8-K filed February 27, 2024 Response filed April 10, 202 |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 10, 2024 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 OraSure Technologies, Inc. 220 East First Street Bethlehem, PA 18015 April 10, 2024 VIA EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Baker, Al Pavot Re: ORASURE TECHNOLOGIES INC Form 10-K filed March 11, 2024 Item 2.02 Form 8-K filed February 27, 2024 File No. 001-16537 Dear L |
|
| April 4, 2024 |
Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www. |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 3, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi |
|
| March 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi |
|
| March 11, 2024 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned constitutes and appoints Michele Anthony and Stefano Taucer, and each of them, her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of Or |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-16537 |
|
| March 11, 2024 |
OraSure Technologies Inc. Compensation Recovery Policy EXHIBIT 97.1 ORASURE TECHNOLOGIES, INC. COMPENSATION RECOVERY POLICY Adopted as of November 14, 2023 OraSure Technologies, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered P |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 27, 2024 |
EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Q4 ‘23 Revenue of $75.9 Million Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 Enters U.S. Syphilis testing market via strategic distribution agreement wi |
|
| February 13, 2024 |
OSUR / OraSure Technologies, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01624-orasuretechnologiesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: OraSure Technologies Inc Title of Class of Securities: Common Stock CUSIP Number: 68554V108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| February 9, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OraSure Technologies Inc (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 4, 2024 |
exhibit991sapphireinves OraSure Technologies, Inc. STRATEGIC PARTNERSHIP & INVESTMENT IN SAPPHIROS JANUARY 4, 2024 Exhibit 99.1 © 2024 OraSure Technologies, Inc. 2 This presentation contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to products, product development and manufacturing activities, the invest |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 4, 2024 |
EXHIBIT 99.2 Investor Contact: Jason Plagman VP, Investor Relations [email protected] Media Contact: Amy Koch Director, Corporate Communications [email protected] OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company The relationship expands OraSure’s innovation pipeline with access to a broad portfolio of k |
|
| December 5, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 5, 2023 |
LLP to the Securities and Exchange Commission, dated December 5, 2023. EXHIBIT 16.1 December 5, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We are currently principal accountants for OraSure Technologies, Inc. (“the Company”) and, under the date of March 3, 2023, we reported on the consolidated financial statements of the Company as of and for the three year period ended December 31, 2022, and the effectiveness of internal con |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Nu |
|
| November 7, 2023 |
EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year Q3 GAAP EPS of $0.15; Q3 Non-GAAP EPS of $0.27 Grew cash balance to $224.9 million as of September 30, 2023 BETHLEHEM, PA, November 7, 2023 (GLO |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number |
|
| August 4, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OraSure Technologies, Inc. |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 3, 2023 |
EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications [email protected] [email protected] OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year InteliSwab® test revenue of $47.5 million in Q2 Q2 Core revenue of $37.9 million grew 4% sequentially and 3% year-over-year Q2 GAAP EPS of $(0.0 |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 16, 2023 |
Amended and Restated OraSure Technologies, Inc. 2000 Stock Award Plan. EXHIBIT 10.1 ORASURE TECHNOLOGIES, INC. STOCK AWARD PLAN ARTICLE 1 ESTABLISHMENT AND PURPOSE (Amended and Restated Effective as of March 31, 2023) Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, and the Plan was approved by shareholders of Epitope, Inc. at the 2000 annual shareholders meeting. Effective September 29, |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2023 |
ou UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ou UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORAS |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 10, 2023 |
EXHIBIT 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ORASURE TECHNOLOGIES, INC. Effective as of May 9, 2023 ARTICLE I Name and Location SECTION 1. Name. The name of the Corporation shall be the name set forth in the Certificate of Incorporation. SECTION 2. Principal Office. The principal office of the Corporation is located at 220 East First Street, Bethlehem, Pennsylvania 18015-1360. SECTION 3. Addi |
|
| May 10, 2023 |
EXHIBIT 99.1 Investor Contact: Scott Gleason SVP Investor Relations & Corp. Communications (484) 425-0588 [email protected] Media Contact: Amy Koch Director, Corporate Communications (484) 523-1815 [email protected] OraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth InteliSwab® test revenue of $118.3 million in Q1, |
|
| April 27, 2023 |
OraSure Technologies Exempt Solicitation PX14A6G 1 x425231px14a6g.htm OraSure Technologies Exempt Solicitation Notice of Exempt Solicitation (Voluntary Submission) Pursuant to Rule 14a-103 Name of the Registrant: OraSure Technologies, Inc. Name of persons relying on exemption: Nia Impact Capital Address of persons relying on exemption: 4900 Shattuck Ave #3648, Oakland, CA 94609 Written materials are submitted pursuant to Rule 14a-6(g)(1) |
|
| April 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 27, 2023 |
As filed with the Securities and Exchange Commission on March 27, 2023 S-8 As filed with the Securities and Exchange Commission on March 27, 2023 Registration No. |
|
| March 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OraSure Technologies, Inc. |
|
| March 27, 2023 |
Form of Inducement Restricted Unit Award Agreement. EX-99.2 Exhibit 99.2 RESTRICTED UNIT INDUCEMENT AWARD AGREEMENT (Performance Vested) (Executive Officers –Employment Agreements) This Restricted Unit Inducement Award Agreement (“Agreement”) is entered into as of [DATE] between OraSure Technologies, Inc,, a Delaware corporation (“OraSure” or the “Company”), and NAME (“Participant”). OraSure hereby awards to the Participant the number of restricted |
|
| March 27, 2023 |
Form of Inducement Restricted Share Award Agreement. EX-99.1 Exhibit 99.1 RESTRICTED SHARE INDUCEMENT AWARD AGREEMENT This Restricted Share Inducement Award Agreement (“Agreement”) is entered into as of [DATE] between OraSure Technologies, Inc., a Delaware corporation (“OraSure” or the “Company”), and [Recipient] (“Participant”). OraSure hereby awards to the Participant the number of restricted shares of OraSure common stock set forth in Section 1.2 |
|
| March 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OraSure Technologies, Inc. |
|
| March 27, 2023 |
Registration Statement No. 333-270861 filed on March 27, 2023 S-8 As filed with the Securities and Exchange Commission on March 27, 2023 Registration No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-16537 ORASURE TECHNOLOGI |
|
| March 3, 2023 |
Exhibit 24 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned constitutes and appoints Michele Anthony and Stefano Taucer and each of them, her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc. |
|
| March 3, 2023 |
EXHIBIT 10.5 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement is entered into on November 7, 2022 (this “Amendment”), by and among Kathleen G. Weber, DNA Genotek, Inc. and OraSure Technologies, Inc. WHEREAS, the parties have entered into an Employment Agreement, dated as of January 1, 2019, and amended that agreement on December 20, 2021 (as amended, the “Employ |
|
| February 14, 2023 |
EXHIBIT 99.1 Investor Contact: Scott Gleason SVP investor Relations & Corporate Communications (484) 425-0588 [email protected] Media Contact: Amy Koch Sr. Manager Corporate Communications (484) 523-1815 [email protected] OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability InteliSwab® revenue of $88.9 million in Q4 |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2023 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 9, 2023 |
OSUR / OraSure Technologies, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01592-orasuretechnologiesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: OraSure Technologies Inc. Title of Class of Securities: Common Stock CUSIP Number: 68554V108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| February 7, 2023 |
OSUR / OraSure Technologies, Inc. / MANAGED ACCOUNT ADVISORS LLC Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 02)* ORASURE TECHNOLOGIES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ORASURE TECHNOLOGIES, INC (Name of Issuer) Common Stock, $0.000001 par value (Title of Class of Securities) 68554V108 (CUSIP Number) February 02, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 2, 2023 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 2, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORA |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
EXHIBIT 99.1 Investor Contact: Scott Gleason SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year InteliSwab? revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test produc |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 12, 2022 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into on August 8, 2022 between KEN MCGRATH (?Employee?) and ORASURE TECHNOLOGIES, INC. (?OraSure? or the ?Company?). WHEREAS, the parties wish to set forth the terms of their relationship and to enter into this Agreement and a confidentiality agreement of even date herewith (the ?Confidentiality Agreement?). |
|
| August 9, 2022 |
EXHIBIT 99.1 Investor Contact: Scott Gleason SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year InteliSwab? revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production Int |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORASURE |
|
| August 9, 2022 |
OraSure 2Q22 Earnings August 9, 2022 EXHIBIT 99.2 Required Disclosures This press release contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations, revenue growth, cost savings, cash flow, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or resu |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporatio |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 26, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into on May 20, 2022 between Carrie Eglinton Manner (?Employee?) and OraSure Technologies, Inc. (?OraSure? or the ?Company?). WHEREAS, the parties wish to set forth the terms of their relationship and to enter into this Agreement and a confidentiality agreement of even date herewith (the ?Confidentiality Agre |
|
| May 26, 2022 |
Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure Exhibit 99.1 Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure May 23, 2022 Company Concludes Strategic Alternative Process Given Market Conditions and its Belief in its Ability to Build on Recent Operational Success BETHLEHEM, Pa., May 23, 2022 (GLOBE NEWSWIRE) ? OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample co |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 19, 2022 As filed with the Securities and Exchange Commission on May 19, 2022 Registration No. |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2022 |
Amended and Restated OraSure Technologies, Inc. 2000 Stock Award Plan EXHIBIT 10.1 ORASURE TECHNOLOGIES, INC. STOCK AWARD PLAN ARTICLE 1 ESTABLISHMENT AND PURPOSE (Amended and Restated Effective as of April 1, 2022) Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, and the Plan was approved by shareholders of Epitope, Inc. at the 2000 annual shareholders meeting. Effective September 29, |
|
| May 18, 2022 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, Pennsylvania 18015 May 18, 2022 OraSure Technologies, Inc. 220 East First Street Bethlehem, Pennsylvania 18015 May 18, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attn: Michael Davis and Celeste Murphy Re: OraSure Technologies, Inc. Registration Statement on Form S-3 Filed February 10, 2022 (File No. 333-262633) Lad |
|
| May 18, 2022 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, Pennsylvania 18015 May 18, 2022 OraSure Technologies, Inc. 220 East First Street Bethlehem, Pennsylvania 18015 May 18, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attn: Michael Davis and Celeste Murphy Re: OraSure Technologies, Inc. Registration Statement on Form S-3 Filed February 10, 2022 (File No. 333-262633) Lad |
|
| May 13, 2022 |
OraSure Technologies, Inc. 220 East First Street Bethlehem, Pennsylvania 18015 May 13, 2022 OraSure Technologies, Inc. 220 East First Street Bethlehem, Pennsylvania 18015 May 13, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attn: Michael Davis and Celeste Murphy Re: OraSure Technologies, Inc. Registration Statement on Form S-3 Filed February 10, 2022 (File No. 333-262633) Lad |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 10, 2022 |
OraSure 1Q22 Earnings May 10, 2022 EXHIBIT 99.2 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORASURE |
|
| May 10, 2022 |
EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO, SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue InteliSwab? revenue of $22.1 million in Q1, up 50% sequentiall |
|
| April 7, 2022 |
DEFA14A 1 d349071ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 7, 2022 |
DEF 14A 1 d330681ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ PreliminaryProxy Statement ☐ Confidential,for Use of the Commi |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 23, 2022 |
Exhibit 10.1 ORASURE TECHNOLOGIES, INC. 220 East First Street Bethlehem, PA USA 18015 March 21, 2022 Via Email Nancy J. Gagliano, M.D. Dear Nancy: On behalf of OraSure Technologies, Inc. (the ?Company?), this letter sets forth the terms of your employment as the Interim Chief Executive Officer of the Company (the ?Interim CEO?). 1. Period of Service: Your employment as Interim CEO will commence on |
|
| March 1, 2022 |
EXHIBIT 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of November 29, 2021 (the ?Effective Date?), between Agnieszka M. Gallagher (?Employee?) and OraSure Technologies, Inc. (?OraSure? or the ?Company?). WHEREAS, the parties wish to set forth the terms of their relationship and to enter into this Agreement and a confidentiality agreement of even date he |
|
| March 1, 2022 |
EXHIBIT 10.13 August 25, 2021 Ms. Michele M. Miller Vice President, Finance and Controller Re: Severance Benefit Dear Michele: As a valued employee of OraSure Technologies, Inc. (the ?Company?), the Company would like to provide you with certain compensation in the event that your employment is terminated by the Company without Cause (as defined below) or by you for Good Reason (as defined below), |
|
| March 1, 2022 |
EXHIBIT 10.10 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement entered into as of December 20, 2021 (this ?Amendment?), by and among Kathleen G. Weber, DNA Genotek, Inc. and OraSure Technologies, Inc. WHEREAS, the parties have previously entered into an Employment Agreement, dated as of January 1, 2019 (the ?Employment Agreement?), and desire to amend the Employ |
|
| March 1, 2022 |
Exhibit 10.30 INDUSTRIAL LEASE BETWEEN Core5 at Laughman Farms Phase 1, LLC AS LANDLORD AND OraSure Technologies, Inc. AS TENANT 9747900?4 LEASE INDEX Section Subject 1 Basic Lease Provisions 2 Premises 3 Term 4 Base Rent 5 Security Deposit 6 Operating Expenses and Additional Rent 7 Utilities 8 Maintenance and Repairs 9 Use of Premises 10 Insurance 11 Indemnity 12 Tenant's Fixtures 13 Signs 14 Gov |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange ACT OF 1934 For the fiscal year ended December 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-16537 ORASURE TECHNOLOGI |
|
| March 1, 2022 |
EXHIBIT 10.20 RESTRICTED UNIT AWARD AGREEMENT (Performance-Vested) (OSUR Executives ?Employment Agreements) This Restricted Unit Award Agreement ("Agreement") is entered into as of February 1, 2021 between OraSure Technologies, Inc., a Delaware corporation ("OraSure" or the ?Company?), and NAME ("Participant"). The OraSure Technologies, Inc. Stock Award Plan (the "Plan") is administered by the Com |
|
| March 1, 2022 |
EX-24 8 osur-ex24.htm EX-24 Exhibit 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Michele Miller and Agnieszka M. Gallagher, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 23, 2022 |
EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab? Production Scales Up Total 2021 revenue of $233.7 million, up 36% year-over year InteliSwab? receives |
|
| February 23, 2022 |
OraSure 4Q21 Earnings February 23, 2022 EXHIBIT 99.2 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could |
|
| February 10, 2022 |
Specimen Certificate representing shares of the Company’s $0.000001 par value Common Stock. Exhibit 4.1 ORASURE TECHNOLOGIES, INC. THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE CORPORATION AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES |
|
| February 10, 2022 |
Form of Indenture to be entered into between the Company and a Trustee acceptable to the Company. Exhibit 4.4.1 FORM OF INDENTURE ORASURE TECHNOLOGIES, INC., as Issuer, and [ ], as Trustee Indenture Dated as of [ ] Providing for the Issuance Of Debt Securities ORASURE TECHNOLOGIES, INC. Reconciliation and tie between Trust Indenture Act of 1939 and indenture, dated as of [ ] Trust Indenture Act Section Indenture Section ?310 (a)(1) 6.07 (a)(2) 6.07 (b) 6.09 ?311 (a) 7.06 (b) 7.06 ?312 (a) 7.01 |
|
| February 10, 2022 |
As filed with the Securities and Exchange Commission on February 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 10, 2022 Registration No. |
|
| February 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) OraSure Technologies, Inc. |
|
| February 10, 2022 |
OSUR / OraSure Technologies, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01591-orasuretechnologiesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: OraSure Technologies Inc. Title of Class of Securities: Common Stock CUSIP Number: 68554V108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box |
|
| January 26, 2022 |
OSUR / OraSure Technologies, Inc. / MANAGED ACCOUNT ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* ORASURE TECHNOLOGIES INC (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2022 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 6, 2022 |
TRANSITION AGREEMENT This Transition Agreement (?Agreement?) is made on January 2, 2022 by and between Stephen S. |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2021 |
EXHIBIT 14.1 ORASURE TECHNOLOGIES, INC. CODE OF BUSINESS CONDUCT AND ETHICS (As amended through November 8, 2021) Introduction The reputation and integrity of OraSure Technologies, Inc. (together with its subsidiaries, the ?Company? or ?we?) are valuable assets that are vital to the Company?s success. Each director, officer and employee of the Company is therefore responsible for conducting the Co |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2021 |
EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO & SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary BETHLE |
|
| November 9, 2021 |
EXHIBIT 10.1 RETIREMENT AGREEMENT This Retirement Agreement (?Agreement?) is made as of November 9, 2021, by and between Jack E. Jerrett (?Executive?) and OraSure Technologies, Inc. (collectively, with its predecessors, successors, affiliates and subsidiaries, the ?Company?) (jointly referred to as the ?Parties? and singularly as a ?Party?): RECITALS WHEREAS, Executive has been employed by the Com |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2021 |
EX-1 2 OSUR13Dex.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated November 08, 2021 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securities and Exchang |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ORASURE TECHNOLOGIES, INC (Name of Issuer) Common stock, $0.000001 par value (Title of Class of Securities) 68554V108 (CUSIP Number) Camber Capital Management LP, 101 Huntington Avenue, Suite 2101, Boston, MA 02199 617-717-6600 (Name, Address and Telephone Number of Person |
|
| November 8, 2021 |
EX-99.1 2 osur-ex991.htm EX-99.1 EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO & SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Technologies Appoints Two New Members to the Board of Directors New Appointments Bring to the Company Significant Executive Leaders |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORA |
|
| November 4, 2021 |
EX-10.2 3 osur-ex102.htm EX-10.2 EXHIBIT 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [***] has been excluded from this exhibit because it is both (i) not material and (ii) is of the type that the registrant treats as private or confidential. SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30 1. REQ |
|
| November 4, 2021 |
Change of Control Severance Letter of Michele Miller, Vice President, Finance and Controller. Exhibit 10.1 August 25, 2021 Ms. Michele M. Miller Vice President, Finance and Controller Re: Severance Benefit Dear Michele: As a valued employee of OraSure Technologies, Inc. (the “Company”), the Company would like to provide you with certain compensation in the event that your employment is terminated by the Company without Cause (as defined below) or by you for Good Reason (as defined below), |
|
| November 3, 2021 |
EX-99.3 4 osur-ex993.htm EX-99.3 OraSure 3Q21 Earnings November 3, 2021 EXHIBIT 99.3 Forward-Looking Statements Disclaimer This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or |
|
| November 3, 2021 |
EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab? Growth in FY22 ? T |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2021 |
EX-99.2 3 osur-ex992.htm EX-99.2 EXHIBIT 99.2 OraSure Technologies, Inc. Third Quarter 2021 Analyst-Investor Conference Call November 3, 2021 Prepared Remarks of Dr. Stephen S. Tang and Scott Gleason Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies third quarter 2021 financial res |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 4, 2021 |
EX-99.1 2 osur-ex991.htm EX-99.1 Exhibit 99.1 Investor Contact: Scott Gleason SVP Investor Relations & Corporate Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Awarded $109 Million Contract from U.S. Department of Defense to Ramp Manufacturing of InteliSwab™ COVID-19 Rapid Test Agreement Ensures OraS |
|
| September 23, 2021 |
EX-99.1 2 osur-20210917ex991.htm EX-99.1 EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO, SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid |
|
| September 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 20, 2021 |
EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO, SVP Investor Relations & Corp. Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Receives $205 Million Procurement Contract for InteliSwab? from the Defense Logistics Agency to Supply Over-the-Counter (OTC) Kits as Part of National Pandemic Respo |
|
| September 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 8, 2021 |
Investor Presentation August 2021 EXHIBIT 99.1 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different |
|
| September 8, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 2, 2021 |
EX-99.1 2 osur-20210827ex991.htm EX-99.1 EXHIBIT 99.1 Investor Contact: Scott Gleason Interim CFO & SVP Investor Relations & Corporate Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 [email protected] OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan Scott Gleason, SVP, Investor Relations and C |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):August 27, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORASURE |
|
| August 3, 2021 |
OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business EXHIBIT 99.1 Investor Contact: Scott Gleason SVP Investor Relations & Corporate Communications 484-425-0588 [email protected] Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-353-1815 [email protected] OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business ? Excluding COVID-19 product revenues, revenues for the second quarter grew 122% |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 3, 2021 |
EX-99.2 3 osur-20210803ex992.htm EX-99.2 EXHIBIT 99.2 OraSure Technologies, Inc. Second Quarter 2021 Analyst-Investor Conference Call August 3, 2021 Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies second quarter 2021 financ |
|
| August 3, 2021 |
EX-99.3 4 osur-20210803ex993.htm EX-99.3 OraSure 2Q21 Earnings August 3, 2021 EXHIBIT 99.3 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual perfo |
|
| July 29, 2021 |
EX-1 2 osur13g2021ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated July 29, 2021 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securities and Exchan |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ORASURE TECHNOLOGIES, INC. (Name of Issuer) Common Stock, $0.000001 par value per share (Title of Class of Securities) 68554V108 (CUSIP Number) July 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORASURE |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2021 |
EX-99.1 2 osur-ex991117.htm EX-99.1 Exhibit 99.1 Investor Contact: Sam Martin Argot Partners 212-600-1902 [email protected] Media Contact Jeanne Mell OraSure Technologies 484-353-1575 [email protected] OraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 M |
|
| May 5, 2021 |
EX-99.3 4 osur-ex993205.htm EX-99.3 OraSure Technologies Investor presentation MAy 2021 Exhibit 99.3 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause ac |
|
| May 5, 2021 |
Exhibit 99.2 OraSure Technologies, Inc. First Quarter 2021 Analyst-Investor Conference Call May 5, 2021 Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca Please see ?Important Information? at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies first quarter 2021 financial results conference call and simultaneous w |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 1, 2021 |
EXHIBIT 99.1 Investor contact: Sam Martin Argot Partners 212-600-1902 [email protected] Media contact: Jeanne Mell OraSure Technologies 484-353-1575 [email protected] OraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of |
|
| March 1, 2021 |
OraSure Technologies Investor presentation March 2021 Exhibit 99.3 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be |
|
| March 1, 2021 |
EX-99.2 3 osur-ex99267.htm EX-99.2 EXHIBIT 99.2 OraSure Technologies, Inc. 2020 Fourth Quarter and Full Year Analyst-Investor Conference Call March 1, 2021 Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies 2020 fourth quarter |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2021 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange ACT OF 1934 For the fiscal year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-16537 ORASURE TECHNOLOGI |
|
| March 1, 2021 |
EX-24 3 osur-ex2410.htm EX-24 Exhibit 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Michele Miller and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* OraSure Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) 12/31/2020 (Date of Event W |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* OraSure Technologies Inc (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: OraSure Technologies Inc. Title of Class of Securities: Common Stock CUSIP Number: 68554V108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ORASURE TECHNOLOGIES INC (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 3, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* OraSure Technologies Inc (Name of Issuer) Common Stock (Title of Class of Securities) 68554V108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 21, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 21, 2020 |
Exhibit 99.1 Investor Contact:Media Contact: Sam MartinJeanne Mell Argot PartnersVP Corporate Communications 212-600-1902484-353-1575 [email protected]@orasure.com OraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Fluid SARS-CoV-2 Antibody Test BETHLEHEM, Pa., December 21, 2020 - OraSure Technologies, Inc. (NASDAQ: OSUR), a lead |
|
| December 21, 2020 |
EX-99.2 3 osur-ex99224.htm EX-99.2 Exhibit 99.2 Questions and Answers Regarding OraSure Technologies, Inc. EUA Application for Lab-based Oral Fluid SARS-CoV-2 Update – December 2020 1. What additional information has FDA requested? • The FDA requested that OraSure perform additional analytical studies related to collection and stability in support of the use of oral fluid as a sample matrix. • The |
|
| December 21, 2020 |
OraSure Technologies Investor presentation december 2020 Exhibit 99.3 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to |
|
| November 5, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2020 |
OraSure Technologies Investor presentation NOVEMBER 2020 Exhibit 99.1 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORA |
|
| November 4, 2020 |
Exhibit 99.1 Investor contact: Media contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 [email protected] [email protected] OraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19 Developments Net Third Quarter Revenues of $48.0 Million Increased 33% Year-Over-Year, Driven by $18.4 Million i |
|
| November 4, 2020 |
Exhibit 99.2 OraSure Technologies, Inc. 2020 Third Quarter Analyst-Investor Conference Call November 4, 2020 Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies 2020 third quarter financial results conference call and simultane |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 1, 2020 |
OraSure Technologies Investor presentation september 2020 Exhibit 99.1 Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to |
|
| September 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 26, 2020 |
Exhibit 24 POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints Michele Miller and Jack E. |
|
| August 26, 2020 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ORASURE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4370966 (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification No.) 220 East First Street Bethlehem, PA 18015 |
|
| August 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 25, 2020 |
OraSure Technologies Summary of Recent CoVID-19 Communications August 25, 2020 Exhibit 99. |
|
| August 10, 2020 |
OSUR / OraSure Technologies, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORASURE |
|
| August 6, 2020 |
EX-10.2 2 osur-ex102142.htm EX-10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of May 11, 2020 (the “Effective Date”), between Lisa A. Nibauer (“Employee”) and OraSure Technologies, Inc. (“OraSure” or the “Company”). WHEREAS, the parties wish to set forth the terms of their relationship and to enter into this Agreement and a confidentiality ag |
|
| August 5, 2020 |
EXHIBIT 99.2 OraSure Technologies, Inc. 2020 Second Quarter Analyst-Investor Conference Call August 5, 2020 Prepared Remarks of Dr. Stephen S. Tang and Roberto Cuca Please see “Important Information” at the conclusion of the following prepared remarks Operator Remarks Good afternoon everyone and welcome to the OraSure Technologies 2020 second quarter financial results conference call and simultane |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2020 |
Exhibit 99.1 Investor contact: Sam Martin Argot Partners 212-600-1902 [email protected] Media contact: Jeanne Mell VP Corporate Communications 484-353-1575 [email protected] OraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs BETHLEHEM, PA, August 5, 2020 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in |
|
| June 4, 2020 |
EX-99.2 Exhibit 99.2 Investor Contact: Media Contact: Sam Martin Jeanne Mell Argot Partners 212-600-1902 VP Corporate Communications 484-353-1575 [email protected] [email protected] OraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock BETHLEHEM, Pa., June 3, 2020 (Globe Newswire) – OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the |
|
| June 4, 2020 |
OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Sam Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 [email protected] [email protected] OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock BETHLEHEM, Pa., June 2, 2020 (Globe Newswire) – OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the |
|
| June 4, 2020 |
EX-1.1 Exhibit 1.1 Execution Version ORASURE TECHNOLOGIES, INC. 8,000,000 Shares of Common Stock Underwriting Agreement June 2, 2020 J.P. Morgan Securities LLC Citigroup Global Markets Inc. and Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Citigroup Global Markets Inc. |
|
| June 4, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 3, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| June 2, 2020 |
OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Sam Martin Jeanne Mell Argot Partners 212-600-1920 VP Corporate Communications 484-353-1575 [email protected] [email protected] OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock BETHLEHEM, Pa., June 1, 2020 (Globe Newswire) – OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announc |
|
| June 2, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| June 2, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 29, 2020 |
ORASURE TECHNOLOGIES APPOINTS LELIO MARMORA TO BOARD OF DIRECTORS Exhibit 99.1 Investor Contact: Sam Martin Argot Partners 212-600-1902 [email protected] Media Contact: Jeanne Mell VP Corporate Communications 484-353-1575 [email protected] ORASURE TECHNOLOGIES APPOINTS LELIO MARMORA TO BOARD OF DIRECTORS BETHLEHEM, PA, May 29, 2020 - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and mi |
|
| May 29, 2020 |
Exhibit 99.2 Company contacts: Investors: Media: Samuel Martin Jeanne Mell Argot Partners VP Corporate Communications 212-600-1902 484-353-1575 [email protected] [email protected] OraSure Technologies, Inc. Announces Purchase of UrSure, Inc. Acquisition strengthens OraSure’s leadership position in HIV field Bethlehem, PA – May 29, 2020 – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader |
|
| May 19, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2020 OraSure Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-16537 36-4370966 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-16537 ORASURE |
|
| May 11, 2020 |
Employment Agreement dated as of May 11, 2020 between OraSure Technologies, Inc. and Lisa A. Nibauer Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of May 11, 2020 (the “Effective Date”), between Lisa A. Nibauer (“Employee”) and OraSure Technologies, Inc. (“OraSure” or the “Company”). WHEREAS, the parties wish to set forth the terms of their relationship and to enter into this Agreement and a confidentiality agreement of even date herewith (the “ |
